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ABSTRACT
A randomised, double-blind, placebo-controlled study examined the safety, tolerance, immunological
effect and anti-human immunodeﬁciency virus (HIV) activity of sub-cutaneously administered HE2000
(16a-bromoepiandrosterone) as monotherapy in treatment-naı¨ve patients with HIV-1. Twenty-four
patients received ﬁve sequential daily doses of 50 or 100 mg of HE2000 or placebo every 6 weeks for up
to three courses, and were followed thereafter for 3 months. HE2000 was safe, with transient injection
site reactions being the main side-effect. Peripheral blood samples, collected serially, were analysed for
changes in immune cell phenotypes. Signiﬁcant increases were observed in the numbers of circulating
dendritic cells, early activated (CD69+CD25–) CD8 T-cells and T-NK cells after administration of 50-mg
doses of HE2000 (p <0.05). Gene expression in peripheral blood mononuclear cells was analysed by real-
time RT-PCR. Before treatment, HIV-1-infected patients had signiﬁcantly elevated transcripts for a
number of inﬂammatory mediators (p <0.012). After 50 mg or 100 mg HE2000, but not after placebo,
there were signiﬁcant sustained decreases in IL-1b, TNF-a, IL-6 and Cox-2 transcripts (p <0.05). There
were no signiﬁcant differences in CD4 cell numbers, although patients receiving 50-mg doses
demonstrated a signiﬁcant decrease in viral load () 0.6 log; p <0.01). Anti-HIV-1 T-cell responses were
analysed serially using GAG-peptides to stimulate cytoplasmic IFN-c responses. After three courses, the
50-mg dose group demonstrated a signiﬁcant increase in CD8 T-cell response against two distinct GAG
peptide pools (p <0.03). These ﬁndings suggest that immune-based therapies may be able to impact viral
load by decreasing inﬂammation and ⁄ or stimulating CD8 T-cells.
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INTRODUCTION
Infection with human immunodeﬁciency virus
(HIV) degrades the immune system, rendering
the host susceptible to opportunistic infections
and death. It is an expanding chronic disease that
currently threatens the lives of more than 40
million people worldwide. 16a-Bromoepiandros-
terone (HE2000) is an immune modulator that has
the potential to stimulate host immune defences
against a pathogen that has already infected the
host. In a preliminary report of a non-human
primate model of simian HIV infection (Frincke
et al., International Society for Antiviral Research,
Jerusalem, 1999), it was reported that HE2000
increased survival time. Furthermore, HE2000
administered to cats infected with feline immu-
nodeﬁciency virus lowered their viral set point
when compared with administration of a placebo
[1].
HE2000 was ﬁrst studied in patients in an
open-label, safety, tolerance, pharmacokinetic
and anti-HIV activity study conducted in South
Africa in treatment-naı¨ve, HIV-infected patients
(Hollis Eden Pharmaceuticals, San Diego, CA,
USA; data on ﬁle). The data indicated increases
in circulating dendritic cell numbers and other
cells important to host protection. Based on
those observations, the present study was
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designed as a randomised, double-blind, pla-
cebo-controlled trial to explore further the
potential of HE2000 to improve the immune
status of patients with HIV-1 infection.
MATERIALS AND METHODS
Study design
Study HE2000-009, conducted in Belville and Durban, South
Africa, between November 2000 and January 2002, was a
randomised, double-blind, placebo-controlled study of the
safety, tolerance, immunological effect and anti-HIV activity of
sub-cutaneously administered HE2000 in HIV-infected, treat-
ment-naı¨ve patients. The inclusion of a vehicle placebo control
and the double-blind randomised design allowed an unbiased
estimation of the contribution of HE2000 to the immune
modulation effects. HE2000 was supplied as a solution
containing 100 mg HE2000 in 1 mL of a vehicle formulation
consisting of PEG200, propylene glycol, benzyl benzoate and
benzyl alcohol (Hollis Eden Pharmaceuticals). The placebo
consisted of the vehicle only, without the active pharmaceu-
tical ingredient HE2000. Patient criteria included female or
male patients, aged >18 years, with a CD4 cell count ‡ 200
cells ⁄mm3, a plasma HIV RNA level between 5 · 103 and
1 · 106 copies ⁄mL, as measured by the bDNA assay (Bayer,
Tarrytown, NY, USA), and a Karnofsky score of at least 70.
Patients did not take anti-retroviral medication during the
treatment or follow-up phases of the study.
Patients were assigned randomly to one of two dose
levels of HE2000 (50 or 100 mg) or to a placebo in a 3:1
ratio. Placebo groups received the equivalent volume of
vehicle as the HE2000 groups (0.5 mL for 50 mg; 1 mL for
100 mg). In this study, a treatment course consisted of 5
consecutive days of once-daily sub-cutaneous injections of
HE2000 or placebo equivalent, followed by a 37-day obser-
vation period. Subjects received up to three 5-day treatment
courses over a 19-week period. All study participants were
provided with a nutritional supplement of multivitamins
with minerals (CentrumTM; Wyeth, Madison, NJ, USA)
throughout the study. The Medicines Control Council, the
regulatory body of the Republic of South Africa, and
the local ethics committees approved the protocol and the
written consent form. The study was conducted in accord-
ance with the International Conference on Harmonization,
Good Clinical Practice Guidelines, National Good Clin-
ical Practice Guidelines and the Declaration of Helsinki
principles.
Flow cytometry
Whole blood was incubated with sets of four monoclonal
antibodies (Becton Dickinson, San Jose, CA, USA) to measure
cell sub-sets using a FACSCalibur (Becton Dickinson). The
four-colour panels consisted of APC, PerCP, FITC and PE
reagents, respectively, in the following combinations: T-cell
activation (CD3 ⁄CD8 ⁄CD69 ⁄CD25, CD3 ⁄CD4 ⁄CD69 ⁄CD25)
[2]; NK populations (CD3 ⁄CD8 ⁄CD16 ⁄CD56); T-cytotoxic cells
(CD3 ⁄CD8 ⁄CCR3 ⁄CCR5); and dendritic cells (CD11c ⁄HLA-
DR ⁄ lineage markers CD3, CD16, CD14, CD19, CD56 ⁄CD123).
List-mode data (25 000–50 000 events) were analysed using
FCS Express (De Novo Software, Thornhill, Ontario, Canada).
CD3+ cell sub-sets were identiﬁed by serial gating of (i)
nucleated cells, (ii) lymphocyte ⁄ lymphoblastoid cells, and (iii)
CD3+ cells, followed by gating of the sub-set of interest. The
absolute frequency per lL of a cell sub-set was estimated by
the following equation:
fðSÞ ¼ pðGÞ  fðGÞ
where G denotes a set of gated cells, S denotes a cell sub-set
contained in the gate, f stands for a frequency (in cells ⁄ lL) in a
set, and p(G) is the proportion of gated cells in the sub-set. For
CD4+ or CD8+ cell sub-sets, p(G) was determined from a CD4+
or CD8+ gated region, and f(G), the absolute CD4+ or CD8+ cell
frequency, was determined using the FACSCount test. For
dendritic cells, p(G) was determined from a nucleated cell
region that was deﬁned using a forward vs. orthogonal scatter
plot, and f(G), the absolute white blood cell (WBC) count, was
determined using an automated cell counter (Advia 120;
Bayer, Tarrytown, NY, USA).
Flow phenotypes were analysed before and serially
throughout the study after HE2000 treatment or placebo.
Results were calculated as percentage change from baseline
(pre-treatment) frequency. Treatment effects were investigated
for dendritic cells (Lineage–HLA–DR+CD11c+ ⁄CD123+) [3],
early activated CD8 T-cells (CD3+CD8+CD69+CD25–) [4,5],
T-NK cells (CD3–CD8+CD16–CD56+) [6,7], and T cytotoxic 1
cells (CD3+CD8+CCR3–CCR5+) [8,9].
Inﬂammatory mediator transcripts
Samples from seven healthy South African donors were
analysed concurrently at two time-points (2 weeks apart),
and from HIV-1-infected patients before and serially through-
out the study after treatment with HE2000 or placebo. Periph-
eral blood was collected into CPT-Vacutainers (Becton Dickin-
son) and peripheral blood mononuclear cells (PBMCs) were
isolated according to the manufacturer’s protocol. Two million
PBMCs were cultured in 1 mL of RPMI 1640 containing fetal
bovine serum 10% v ⁄v for 3 h at 37C to establish baseline
transcription levels. After lysis in 300 lL MagnaPure lysis
buffer (Roche, Branchburg, NJ, USA), the samples were frozen
at ) 70C. After thawing, the lysates were mixed and trans-
ferred into the MagnaPure sample cartridge, and mRNA was
isolated with the MagnaPure-LC apparatus (Roche) using the
mRNA standard protocol for cells. The elution volume was set
to 50 lL. Two aliquots of 8.2 lL RNA were independently
reverse-transcribed using AMV-reverse transcriptase and
oligo-(dT) as primer (First Strand cDNA synthesis kit; Roche)
according to the manufacturer’s recommendations. After ter-
mination of the cDNA synthesis, the reaction mix was diluted
to a ﬁnal volume of 500 lL and stored at ) 20C until PCR
analysis.
Target sequences were ampliﬁed using LightCycler Primer
Sets (designed by T. Giese; Search-LC, Heidelberg, Germany)
with the LightCycler FastStart DNA Sybr Green I Kit (Roche)
according to the manufacturer’s protocol. RNA input was
normalised by the average expression of two housekeeping
genes, b-actin and cyclophilin B, in healthy donors. As this
factor remained constant, all samples were deemed compar-
able.
The copy number was calculated from a standard curve,
obtained by regressing known input concentrations of a
plasmid vs. the PCR cycle number at which the detected
ﬂuorescence intensity reached a speciﬁc value. Results from
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two independent analyses for each sample and parameters
were averaged and presented as adjusted transcripts ⁄ lL
cDNA.
Cell-mediated immunity
Frozen PBMCs were thawed and stimulated separately with
two pools of HIV GAG peptides (GAG pool 1 and GAG pool 2;
C. Brander, Massachusetts General Hospital, Boston, MA,
USA), and with anti-CD49d and anti-CD28. Cells were
permeabilised and stained with CD4, CD8, CD69 and IFN-c
antibodies, and were then analysed for cytoplasmic IFN-c
production by multiparameter ﬂow cytometry.
CD4 and viral load determinations
CD4 counts were assessed using a FACSCount (Becton
Dickinson), and viral loads were measured using the bDNA
assay. Quality assurance procedures were adhered to for
bDNA, and internal and external controls were used to
validate each batch of samples. Average log10 changes in viral
loads were calculated as the average for each dose group of the
change from log10 baseline values for individual patients at
each visit.
Statistical methods
The study was designed to explore the safety of HE2000 and to
understand its effects on immunological biomarkers. Thus, it
was not powered to formally detect efﬁcacy in any parameter.
Demographical and background characteristics of the treat-
ment groups at baseline were compared by exact Wilcoxon and
exact chi-square tests. For any given patient response yt at time
t, the percentage change from baseline was deﬁned as 100*(yt –
y0) ⁄ y0, where y0 denotes the patient baseline response. Hence, a
negative value indicates a decrease from baseline. Percentage
changes were tested for their absolute signiﬁcance with the
exact Wilcoxon signed rank test and pairwise by treatments
with the exact Wilcoxon Mann–Whitney test. All comparisons
were adjusted for multiplicity by means of the step-down
Bonferroni method. Each individual GAG response was pre-
served in the analysis. Baseline values entered the model as co-
variates. The time-series structure of the study design extended
from 21 days before baseline to day 133, plus three monthly
follow-up visits. Resulting time-sequences were submitted to
generalised linear mixed models [10]. These models allow for
heterogeneous variances and non-normal responses. Analyses
were performed with the original data and via Savage scores
for skewed distributions. Overall signiﬁcant results were
followed by pairwise comparisons adjusted for multiplicity.
Statistical analyses were performed with the use of SAS
software (SAS Institute, Cary, NC, USA) and StatXact software
(Cytel Software Corp., Cambridge, MA, USA) to calculate exact
p values.
RESULTS
Baseline characteristics and disposition of
patients
The disposition of patients for analysis is presen-
ted in Table 1. All patients in the HE2000 50-mg
group completed the study. One patient in the
placebo group did not complete the study
because of a protocol violation. Three patients in
the HE2000 100-mg group were discontinued
from the study: one became pregnant, one was
lost to follow-up, and one withdrew consent. No
patients died during this study or discontinued
treatment during the trial because of treatment-
related adverse events. The baseline charac-
teristics of the patients are listed in Table 2.
Randomisation resulted in balanced distribution
concerning age, gender, race or ethnic group, viral
load and CD4 count, considering the small sam-
ple size.
Safety
All 24 patients were considered in the safety
analysis. The most commonly reported treatment-
related adverse events were injection site reac-
tions. Local reactions, including pain, erythaema,
induration, burning, swelling and pruritis,
Table 1. Disposition of patients according to treatment
Group
HE2000
50 mg 100 mg Placebo Total
Enrolled (24)a 9 (37.5) 9 (37.5) 6 (25.0) 24
Completed (20) 9 (37.5) 6 (25.0) 5 (20.8) 20
Discontinued (4) 0 (0) 3 (12.5) 1 (4.2) 4
Reason
Protocol violation 0 (0) 0 (0) 1 (4.2) 1
Consent withdrawn 0 (0) 1 (4.2) 0 (0) 1
Lost to follow-up 0 (0) 1 (4.2) 0 (0) 1
Terminated by investigator 0 (0) 1 (4.2) 0 (0) 1
aSample size and percentage relative to row total.
Table 2. Baseline characteristics of patients included in
the study
Characteristic
HE2000
50 mg 100 mg Placebo
n a 9 9 6
Age, years 35 (28,38)b 31 (28,37)h 44.5 (41,50)
Gender, F ⁄Mc 6 ⁄ 3 7 ⁄ 2 2 ⁄ 4
Raced, n (%)
African 7 (29.2) 5 (20.8) 5 (20.8)
Caucasian 1 (4.2) 1 (4.2) 0 (0)
Other 1 (4.2) 3 (12.5) 1 (4.2)
Viral loade 38 (14,58) b 25 (14,81) 36 (14,66)
CD4 countf 482 (354 568)b 382 (267 438) 287 (247 482)g
aSample size.
bMedian (inter-quartile range).
cFemale ⁄male.
dRace or ethnic group.
e103 copies ⁄mL.
fCD4+ cells ⁄ lL.
gBased on n = 5 (one patient without baseline value).
h100 mg group vs. placebo, p < 0.04.
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occurred in 8 ⁄ 9, 9 ⁄ 9 and 4 ⁄ 6 patients in the 50-
mg, 100-mg and placebo groups, respectively.
These reactions were described as transient and
mild-to-moderate in severity.
Changes in immune phenotypes
Changes in the numbers of cell subsets were
analysed for dendritic cells, early activated CD8
T-cells, T-NK cells and T cytotoxic 1 (Tc1) cells.
The changes in immune phenotypes from base-
line values are shown in Table 3. In the placebo
group there was a signiﬁcant decrease in T-NK
cells (p <0.05). Patients in the 50-mg dose group
showed signiﬁcant increases in dendritic cells
(p <0.05) and activated CD8 T-cells (p <0.01).
Patients in the 100-mg dose group had a
signiﬁcant increase in Tc1 cells (p <0.05). Pairwise
comparisons demonstrated signiﬁcant differences
(p <0.05) between the 50-mg and placebo groups
for dendritic cells, activated CD8 T-cells and
T-NK cells.
Changes in inﬂammatory mediator transcripts
HIV-1-infected patients displayed elevated levels
of a number of inﬂammation-related transcripts
in their circulating mononuclear cells before
treatment compared with healthy volunteers
(Table 4). Each pairwise comparison was signiﬁ-
cant after adjustment for multiple testing
(p <0.012).
Serial analyses during the study showed no
signiﬁcant change in the levels of transcripts for
four inﬂammatory mediators (IL-1b, TNF-a, IL-6
and Cox-2) in the placebo group (Table 5),
whereas both the 50-mg and 100-mg dose groups
showed signiﬁcant decreases (p <0.05 and
p <0.01, respectively) in transcripts for all four
mediators. Decreases were observed in the treated
groups after the ﬁrst course of treatment, and
these persisted throughout the study. The differ-
ences between each HE2000 group and the
placebo group were signiﬁcant for IL-1b, TNF-a
and Cox-2 (p <0.05), and there were trends for
IL-6 (p < 0.07 for both HE2000 groups).
Changes in circulating CD4 cells and viral loads
There were no signiﬁcant changes in the num-
bers of circulating CD4 and CD8 T-lymphocytes
between groups. Fig. 1 shows the average log10
changes in viral loads over time. At the end of
the study, on average, the 50-mg dose group
showed a ) 0.66 log change in viral load, the
100-mg group showed a ) 0.45 log change, and
the placebo group showed a ) 0.19 log change
from baseline values. A statistically signiﬁcant
downward linear component was detected in
the viral load of the 50-mg dose group relative
Table 3. Percentage change from baseline in cell subsets
Cell subseta
%b vs. own baseline %c vs. placebo
50 mg
n = 9
100 mg
n = 9
Placebo
n = 6 50 mg 100 mg
Dendritic 13.6* 0.0 ) 7.0 20.6* 7.0
Act. CD8 24.6** 3.1 ) 3.5 28.1* 6.6
T-NK 12.2 0.2 ) 18.6* 30.8* 18.8
Tc1 14.0 34.6* 1.5 12.5 33.1
aDendritic cells: lineage–HLA–DR+CD11c+ ⁄CD123+ Act: CD8: CD3+, CD8+, CD69+,
CD25–; T-NK cells: CD3–CD8+CD16–CD56+ Tc1 cells: CD3+, CD8+, CCR3–, CCR5+.
bComparison of average percentage change from baseline.
cPairwise comparisons of active treatment minus placebo.
*p <0.05; **p <0.01.
Table 4. Inﬂammatory mediator transcripts in healthy
donors and human immunodeﬁciency virus (HIV)-1
patients pre-treatment
Gene
Median transcript levels
Healthy donors
n = 7
HIV patients*
n = 22
IL-1b 1973 19 662
TNF-a 99 1133
MIP-1a 616 15 732
IL-6 36 1543
IL-8 5425 56 909
IL-10 6 15
Cox-2 160 1255
M-CSF 14 211
RANTES 52 191
GM-CSF 1 105
MCP-1 1008 7224
IFN-c 7 41
*p <0.012 in all cases.
Table 5. Selected inﬂammatory mediator transcript chan-
ges after treatment
Gene
Median percentage change from baseline
Treatmenta Treatment comparisonsb
50 mg
(n = 7)
100 mg
(n = 9)
Placebo
(n = 6)
50 mg vs.
Placebo
100 mg vs.
placebo
IL-1b ) 65* ) 66** ) 19 ) 46* ) 47*
TNF-a ) 82* ) 79** 0.3 ) 82* ) 79*
IL-6 ) 83* ) 90** 0.9 ) 84# ) 91#
Cox-2 ) 60* ) 58** ) 17 ) 43* ) 41*
ap values refer to the signiﬁcance relative to 0% change.
bp values adjusted for multiplicity.
*p <0.05. **p <0.01. #p < 0.07.
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the group receiving placebo (p <0.01). The
estimated regression coefﬁcients were )0.00294
(log10 ⁄day) for the 50-mg group (p <0.001), and
)0.00084 (log10 ⁄day) for the placebo group
(p < 0.33).
Cellular immunity to HIV
There were no signiﬁcant differences in HIV GAG
peptide cytoplasmic IFN-c responses in CD4
T-cells between treated and placebo groups.
Similarly, there were no signiﬁcant differences
between groups during the dosing period (up to
day 89) (data not shown). Because of a potential
time-lag to improve the immune response in
HIV-1 infected patients, and because the viral
load change in the 50-mg dose group only
became apparent after dosing (days 102–219),
cellular immune responses were investigated
during this period. Cytoplasmic cytokine analy-
ses were performed on patients with baseline
samples, and were available for seven patients in
the 100-mg group, four patients in the 50-mg
group, and four patients in the placebo group.
Fig. 2 shows an increase in CD8 T-cell response to
both GAG pool 1 and GAG pool 2, respectively,
during this period, reaching 0.7% of the CD8
T-cells with GAG pool 1 and 1.5% with GAG
pool 2 for the 50-mg group. Similar responses
were not seen in the 100-mg dose group or the
placebo group. Comparisons among the groups
indicated that the changes observed were signi-
ﬁcant for the 50-mg dose group as opposed to
both the placebo (p 0.005 for GAG pool 1; p 0.03
for GAG pool 2) and the 100-mg dose group
(p 0.02 for GAG pool 1; p 0.001 for GAG pool 2)
(Table 6).
DISCUSSION
HE2000, at both doses studied, signiﬁcantly
decreased IL1-b, TNF-a, IL-6 and Cox-2 transcripts
associated with a chronic inﬂammatory state. This
decrease in the chronic inﬂammatory state asso-
ciated with HIV-1 infection may lead to an
improvement in innate and adaptive immunity.
Patients infected with HIV-1 produce elevated
inﬂammatory mediators [11–13]. One of the chal-
lenges of immune therapy for HIV-1 infection is
to decrease the non-speciﬁc chronic inﬂammatory
Fig. 1. Average log10 change in viral load for each dose
group.
Fig. 2. Cytoplasmic CD8 T-cell IFN-c responses to (A)
GAG peptide pool 1 and (B) GAG peptide pool 2. Baseline
values are indicated at day 1.
Table 6. CD8 T-cell cytoplasmic IFN-c responses to pep-
tides
GAG
peptides Comparison
Differencea
(SEM) pb
Adjusted
pc
Pool 1 100 mg vs. 50 mg ) 24% (8%) 0.008 0.02
100 mg vs. placebo 10% (9%) 0.35 1.0
50 mg vs. placebo 32% (9%) 0.002 0.005
Pool 2 100 mg vs. 50 mg ) 34% (11%) 0.0004 0.001
100 mg vs. placebo 2% (13%) 0.4 1.0
50 mg vs. placebo 37% (15%) 0.004 0.03
aDifference in treatment means.
bRaw p values for the signiﬁcance of the difference.
cp values adjusted for multiplicity by the Bonferroni procedure. SEM; standard
error of the mean.
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process, while improving speciﬁc immune
responses. Administration of anti-inﬂammatory
agents to HIV-1 patients can decrease speciﬁc
immunity [14–16], while administration of IL-2 (to
improve immunity) leads to increases in pro-
inﬂammatory mediators, prompting immunosup-
pressive therapy [14].
Evidence is also presented for improvement in
innate and adaptive immune components after
treatment with HE2000. Dendritic cells and acti-
vated CD8 T-cells increased after treatment with
50 mg of HE2000. T-NK cells decreased over time
in the placebo group, but not in the HE2000
groups. T-cytotoxic cells (Tc1) increased in num-
ber with 100 mg of HE2000. Circulating dendritic
cell numbers are decreased in HIV-1 patients [17–
19]. CD8+CD69+ T-cells, associated with in-vitro
responses from control and HIV-infected patients
[20,21], and with early in-vivo responses to simian
immunodeﬁciency virus infection [22–24], were
also decreased in HIV patients [25]. Decreased
CD56 expression on CD8 T-NK cells may be
associated with decreased T-cell cytotoxicity in
individuals infected with HIV-1 [26] or hepatitis C
virus [27]. These cells are implicated in the
production of soluble factors that inhibit HIV-1
replication [28] as well as IFN-c [29]. The improve-
ment in innate and adaptive immunity might be
expected to result in a decrease in viral load, and
an enhanced ability to prevent opportunistic
infections.
HIV-1 GAG peptide-speciﬁc CD8 IFN-c
responses were analysed in order to investigate
the speciﬁcity of the observed stimulation of
adaptive immunity. An increase in speciﬁc
responses in the 50-mg dose group was demon-
strated, concomitant with a signiﬁcant decrease
() 0.6 log) in viral load. This prompts speculation
that the increases observed in circulating dend-
ritic cells and early activated CD8 T-cells might
have contributed to the generation of HIV-1-
speciﬁc CD8 responses that might, in turn, con-
tribute to the observed decrease in viral load. The
possible contribution of T-NK cells to these
observations is unknown. All patients were sup-
plied with daily doses of multivitamins to control
for nutritional effects on immunity [30–33], and
this supplementation is expected to contribute to
the minimal effects observed in the placebo group
when compared with an untreated population.
The decrease in viral load was not accompanied
by a concomitant increase in circulating CD4
T-cells. It is possible that HE2000 treatment also
results in CD4 cells remaining in the peripheral
sites combating infection.
The reasons for the differences observed
between the 50-mg and 100-mg dose groups are
unclear. This was a pilot study, with three of the
nine patients in the 100-mg dose group discon-
tinuing the trial. Daynes et al. [34] have shown a
biphasic IL-2 response by lymphocytes from the
action of dehydroepiandrosterone in mice [34]
and in human cells [35]. The diminished response
with higher doses of HE2000 may be explained by
these observations.
The improvement in innate and adaptive
immunity may extend beyond early HIV-1 infec-
tion. It has also been demonstrated that HE2000
has activity in a murine model of tuberculosis
[36], restoring Th1 responses and accelerating
chemotherapy-induced bacterial clearance. Fur-
thermore, HE2000 can lead to malarial parasite
clearance in a rat model [37]. The results from the
present study were obtained in the absence of
anti-retroviral drugs. With further clinical devel-
opment, this compound might prove useful in
combination with anti-retroviral drugs for the
treatment of HIV-infected patients.
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